Previous 10 | Next 10 |
Shares of STAAR Surgical (NASDAQ: STAA) were surging 10.9% higher as of 11:17 a.m. ET after rising as much as 19.4% earlier in the day. The big gain came after the company announced that the U.S. Food and Drug Administration (FDA) approved the EVO/EVO+ Visian Implantable Collamer Le...
Gainers: ORIC Pharmaceuticals (ORIC) +19%. Aptorum (APM) +16%. STAAR Surgical (STAA) +16%. Creative Medical Technology (CELZ) +13%. Tempest Therapeutics (TPST) +11%. Losers: NeuroOne Medical Technologies (NMTC) -48%. Clever Leaves (CLVR) -26%. Capricor ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! It’s time to start off the week with an overview of the biggest pre-market stock movers for Monday! Source: f11photo/Shutterstock.com A reverse stock split, earnings, FDA approval, and m...
The U.S. Food and Drug Administration (FDA) approved STAAR Surgical's (NASDAQ:STAA) EVO/EVO+ Visian Implantable Collamer Lens for the correction of myopia and myopia with astigmatism. The company said than an estimated 100M U.S. adults ages 21 to 45 who have myopia are potential ca...
EVO Lenses Provide Visual Freedom from Contact Lenses and Glasses Over One Million EVO Lenses Have Already Been Implanted Worldwide Information for Patients and Doctor Finder at DiscoverEVO.com STAAR Surgical Company (NASDAQ: STAA), a leading developer, manuf...
Two sample Breakout Stocks for Week 12 with better than 10% short-term upside potential and a Dow stock pick. The Momentum Gauge® signal has finally turned positive into 2022 with an official buy signal this week and total average YTD returns without the buy signal are at +42.2%....
STAAR Surgical (NASDAQ:STAA), a maker of implantable eye lenses, is trading ~2% higher in the pre-market Friday after BTIG upgraded it to Buy from Neutral, citing a compelling valuation as the company prepares to launch its EVO family of myopia lenses. Underperforming the broader ma...
STAAR Surgical (STAA +11.7%) stock rose following its earnings results, where Q4 net sales grew 28% Y/Y to $59M. The company said the increase was driven by ICL sales and unit growth of 33% and 36%, respectively, as compared to the prior year period. Other product sales decreased 3% comp...
STAAR Surgical Company (STAA) Q4 2021 Earnings Conference Call February 23, 2022, 04:30 PM ET Company Participants Brian Moore - Vice President, Investor, Media Relations and Corporate Development Caren Mason - President and Chief Executive Officer Patrick Williams - Chief Financial Officer C...
STAAR Surgical press release (NASDAQ:STAA): Q4 Non-GAAP EPS of $0.19 beats by $0.03. Revenue of $59M (+28.3% Y/Y) misses by $0.21M. For further details see: STAAR Surgical Non-GAAP EPS of $0.19 beats by $0.03, revenue of $59M misses by $0.21M
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
2024-07-14 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...